Our Pricing

Buy Wegovy Online UK: BMI Requirements & Eligibility

Published on: June 03, 2026

If you're looking to buy Wegovy online UK BMI requirements are the first hurdle to understand. At Cured Pharmacy, we provide transparent eligibility guidance alongside genuine UK-licensed Wegovy from £79.00, with free clinical assessment by our registered prescribers. Understanding whether you meet the MHRA-approved criteria is essential before starting treatment.

Wegovy BMI Requirements in the UK

Wegovy (semaglutide 2.4mg) is licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above if you have at least one weight-related health condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. These thresholds align with NICE guidance and ensure the medication is prescribed to those who will benefit most from its mechanism of action.

Your BMI is calculated by dividing your weight in kilograms by your height in metres squared. For example, someone weighing 90kg and standing 1.75m tall has a BMI of approximately 29.4 kg/m². If you're close to the threshold but have comorbidities like prediabetes or cardiovascular risk factors, you may still qualify under the lower BMI criterion, subject to prescriber approval.

It's important to note that BMI requirements exist not as arbitrary barriers, but because clinical trial data from the STEP programme demonstrated significant efficacy and safety specifically in these patient populations [1][2]. Our superintendent pharmacist Tarun Kumar and the clinical team at Cured Pharmacy assess each patient individually against these evidence-based criteria during your free online consultation.

Who Is Eligible for Wegovy Treatment?

Beyond BMI, Wegovy eligibility in the UK depends on several clinical factors. You must be aged 18 or over, have attempted weight loss through diet and exercise, and have no contraindications such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. Pregnant or breastfeeding women cannot use Wegovy, and those with severe gastrointestinal disease may be advised against treatment.

Weight-related comorbidities that support eligibility at the lower BMI threshold of 27 kg/m² include diagnosed type 2 diabetes, hypertension requiring medication, dyslipidaemia, cardiovascular disease, or obstructive sleep apnoea. These conditions significantly increase health risks associated with excess weight, and semaglutide has been shown in clinical trials to improve glycaemic control and cardiovascular outcomes alongside weight reduction [2][3].

During your online consultation at Cured Pharmacy, a UK-registered prescriber will review your full medical history, current medications, and any previous weight loss attempts. This ensures Wegovy is both safe and appropriate for your individual circumstances, in line with GMC and GPhC professional standards.

Medical Conditions That May Affect Eligibility

Certain medical conditions require careful consideration before prescribing Wegovy. Active thyroid disease, a history of pancreatitis, diabetic retinopathy complications, or severe renal impairment may influence whether Wegovy is the safest choice for you. Your prescriber will assess these factors during consultation and may recommend alternative treatments or additional monitoring if Wegovy is prescribed.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone involved in appetite regulation and glucose metabolism [1]. By activating GLP-1 receptors in the brain, semaglutide reduces hunger signals, increases feelings of fullness after eating, and slows gastric emptying. This multi-pathway approach helps patients consume fewer calories without the intense hunger that often derails traditional dieting.

In the landmark STEP 1 trial, participants using semaglutide 2.4mg weekly achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [2]. Importantly, 86.4% of patients on Wegovy lost at least 5% of their body weight — a threshold associated with meaningful improvements in cardiovascular and metabolic health markers.

Wegovy is administered via a pre-filled, single-use injection pen once weekly, typically on the same day each week. Treatment begins at a low dose of 0.25mg, gradually escalating over 16-20 weeks to the maintenance dose of 2.4mg. This dose titration minimises gastrointestinal side effects such as nausea and allows your body to adapt to the medication's effects.

Expected Results and Timeline

Most patients begin noticing reduced appetite within the first 2-4 weeks of treatment, with measurable weight loss typically evident by week 8-12. Clinical trial data shows the majority of weight loss occurs within the first 60 weeks, plateauing thereafter [2]. Your UK prescriber will monitor your progress and may adjust treatment if you do not achieve at least 5% weight loss after 12-16 weeks at the maintenance dose, as per NICE recommendations.

Wegovy vs Alternative Weight Loss Treatments

While Wegovy is highly effective, it's one of several licensed weight management options available through Cured Pharmacy. Understanding how it compares to alternatives helps you and your prescriber choose the most suitable treatment for your circumstances and preferences.

Orlistat, available as the branded Xenical or generic formulation, works by blocking fat absorption in the gut rather than affecting appetite hormones. It requires a lower BMI threshold (28 kg/m² with comorbidities) and is taken three times daily with meals. Clinical trials show average weight loss of 5-10% when combined with a reduced-calorie diet, making it less potent than GLP-1 treatments but suitable for patients who prefer oral medication or have contraindications to injectables [4].

Mysimba (naltrexone/bupropion) is an oral combination tablet that acts on the central nervous system to reduce cravings and appetite. It may be appropriate for patients who cannot tolerate GLP-1 side effects or prefer not to use injections, though average weight loss is typically lower than with Wegovy. Your prescriber will discuss these alternatives during consultation if Wegovy is not suitable or if you wish to explore other options.

Starting Wegovy at Cured Pharmacy

Beginning your Wegovy treatment at Cured Pharmacy is straightforward and designed with patient convenience in mind. Start by completing our free online consultation, which takes under three minutes and covers your medical history, current health conditions, medications, and weight loss goals. This assessment is reviewed by a UK-registered prescriber, typically within 24 hours on working days.

If approved, your prescription is sent directly to our UK-registered pharmacy (GPhC 9012511), where our team dispenses genuine UK-licensed Wegovy pens. We offer discreet, secure delivery to your home or workplace, with tracking provided for your peace of mind. Pricing is transparent from the outset — Wegovy starts from £79.00 per pen, with no hidden consultation fees or subscription traps.

Our clinical team remains available throughout your treatment journey. You can contact us at (+44) 116 4646009 if you have questions about dosing, side effects, or need to adjust your prescription. Ongoing monitoring is essential for safe, effective weight management, and we encourage regular check-ins with your prescriber as you progress through the dose escalation schedule.

What to Expect During Your Consultation

Your online consultation will ask detailed questions about your weight history, previous weight loss attempts, current BMI, any weight-related health conditions, and medications you're taking. Be honest and thorough — this information ensures your prescriber can make a safe, informed decision. If additional information is needed, our clinical team will contact you directly before issuing a prescription.

Managing Side Effects and Optimising Results

Like all medications, Wegovy can cause side effects, most commonly gastrointestinal symptoms such as nausea, diarrhoea, constipation, and abdominal discomfort [2]. These effects are usually mild to moderate, occur most frequently during dose escalation, and typically diminish as your body adjusts to the medication. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise nausea.

Rare but serious side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and hypoglycaemia in patients taking other glucose-lowering medications. If you experience persistent severe abdominal pain, visual changes, or signs of an allergic reaction, stop taking Wegovy and seek immediate medical attention. Our pharmacist Tarun Kumar and the clinical team are available to discuss any concerns you have about side effects.

To optimise your results with Wegovy, combine treatment with sustainable lifestyle changes. Clinical trials demonstrate that patients who adopt a reduced-calorie diet and increase physical activity achieve greater weight loss than those relying on medication alone [2][3]. Aim for a balanced diet rich in vegetables, lean protein, and whole grains, and incorporate at least 150 minutes of moderate-intensity exercise weekly, as recommended by NHS guidelines.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen (semaglutide). GOV.UK. [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2022). Obesity: identification, assessment and management (CG189). NICE. [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary.